论文部分内容阅读
目的观察乌司他汀对重症肺炎患者的肺保护作用,及对住院时间和住院费用的影响。方法将115例急性重症肺炎患者分为乌司他汀治疗组和对照组。对照组进行常规治疗,治疗组在进行常规治疗基础上加用乌司他汀,对比2组患者的临床疗效,治疗前、治疗后第7天C反应蛋白(CRP)、血气、胸片、体温(T)、呼吸(RR)、心率(HR)、血白细胞(WBC)、氧合指数(PaO2/F iO2)、临床肺部感染评分(CPIS)、APACHE-II评分、住院时间及住院费用等。结果治疗组CRP、T、RR、HR、WBC、PaO2/F iO2、CPIS、APACHE-II改善情况明显优于对照组(P<0.05);2组总有效率分别为89.3%、66.1%,差异有统计学意义(P<0.05);治疗组ICU住院时间少于对照组,住院费用减少,差异有统计学意义(P<0.05)。结论乌司他丁辅助治疗重症肺炎患者,可有效减轻患者病情,改善各项炎症指标及氧合指数,减少ICU住院时间,降低住院费用。
Objective To observe the protective effects of ulinastatin on patients with severe pneumonia and its influence on hospitalization and hospitalization costs. Methods One hundred and fifteen patients with acute severe pneumonia were divided into ulinastatin group and control group. The patients in the control group were given routine treatment. The treatment group was treated with ulinastatin on the basis of routine treatment. The clinical efficacy of the two groups were compared. Before treatment, C-reactive protein (CRP), blood gas, chest radiograph, body temperature T, RR, WBC, PaO2 / F iO2, CPIS, APACHE-II score, length of stay and cost of hospitalization. Results The improvement of CRP, T, RR, HR, WBC, PaO2 / F iO2, CPIS and APACHE-II in the treatment group was significantly better than that in the control group (P <0.05). The total effective rates in the two groups were 89.3% and 66.1% (P <0.05). The hospitalization time of ICU in the treatment group was less than that in the control group, and the hospitalization cost was decreased, the difference was statistically significant (P <0.05). Conclusion The ulinastatin adjuvant treatment of patients with severe pneumonia can effectively reduce the patient’s condition, improve the inflammation index and oxygenation index, reduce ICU length of stay and reduce hospitalization costs.